Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $71.5 million.

  • Kymera Therapeutics' Shares Outstanding (Weighted Average) rose 10.39% to $71.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.5 million, marking a year-over-year increase of 10.39%. This contributed to the annual value of $64.9 million for FY2024, which is 6.27% up from last year.
  • Kymera Therapeutics' Shares Outstanding (Weighted Average) amounted to $71.5 million in Q3 2025, which was up 9.79% from $65.1 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $71.5 million for Q3 2025, and its period low was $45.0 million during Q1 2021.
  • Over the past 3 years, Kymera Therapeutics' median Shares Outstanding (Weighted Average) value was $61.8 million (recorded in 2024), while the average stood at $62.0 million.
  • Data for Kymera Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY grew of 16.72% (in 2024) over the last 5 years.
  • Over the past 5 years, Kymera Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $51.4 million in 2021, then rose by 7.39% to $55.2 million in 2022, then rose by 10.74% to $61.1 million in 2023, then increased by 6.27% to $64.9 million in 2024, then increased by 10.39% to $71.5 million in 2025.
  • Its last three reported values are $71.5 million in Q3 2025, $65.1 million for Q2 2025, and $65.1 million during Q1 2025.